Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. ...
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 51
- Registration Number
- NCT02279394
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT02252263
- Locations
- 🇪🇸
Local Institution, Pamplona, Navarra, Spain
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT02159365
- Locations
- 🇺🇸
Baptist Health Medical Group Oncology, Miami, Florida, United States
🇺🇸Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸Comprehensive Blood And Cancer Center, Bakersfield, California, United States
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 142
- Registration Number
- NCT01668719
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸The Mark H Zangmeister Center, Columbus, Ohio, United States
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
- Conditions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Facet Biotech
- Target Recruit Count
- 35
- Registration Number
- NCT00425347
- Locations
- 🇺🇸
USC/Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.